Editas Medicine (EDIT) Net Cash Flow (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Net Cash Flow of $25.9 million for Q3 2025, down 17.5% year-over-year from $31.4 million in Q3 2024, and up 17366.0% quarter-over-quarter from -$150000.0 in Q2 2025.
Editas Medicine (EDIT) Net Cash Flow (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Net Cash Flow for 11 consecutive years, with $25.9 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Cash Flow fell 17.5% year-over-year to $25.9 million; the TTM figure through Dec 2025 stood at $32.9 million (up 317.04% YoY), while the FY2024 annual figure was $7.9 million, up 144.15% from the prior year.
- Net Cash Flow improved to $25.9 million in Q3 2025 per EDIT's latest filing, from -$150000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $215.2 million in Q1 2021 and bottomed at -$138.3 million in Q3 2023.
- Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of -$150000.0 in 2025.
- Annual changes were most pronounced in 2021 — Net Cash Flow soared 4804.61% — and 2023, when it plunged 434.79%.
- Editas Medicine's Net Cash Flow stood at -$56.4 million in 2021, then declined by 22.74% to -$69.2 million in 2022, then surged by 159.43% to $41.1 million in 2023, then slipped by 13.15% to $35.7 million in 2024, then fell by 27.47% to $25.9 million in 2025.
- Business Quant data shows EDIT's Net Cash Flow at $25.9 million in Q3 2025, -$150000.0 in Q2 2025, and $7.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 25.90 Mn |
| Sep 30, 2025 | 25.90 Mn |
| Jun 30, 2025 | -150,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Mar 31, 2025 | 7.15 Mn |
| Mar 31, 2025 | 7.15 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Sep 30, 2024 | 31.39 Mn |
| Sep 30, 2024 | 31.39 Mn |
| Jun 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -4.79 Mn |
| Mar 31, 2024 | -54.43 Mn |
| Mar 31, 2024 | -54.43 Mn |
| Dec 31, 2023 | 41.11 Mn |
| Dec 31, 2023 | 41.11 Mn |
| Sep 30, 2023 | -138.28 Mn |
| Sep 30, 2023 | -138.28 Mn |
| Jun 30, 2023 | 91.80 Mn |
| Jun 30, 2023 | 91.80 Mn |